Home / Deep Research / Leptospirosis

Leptospirosis

Disease Pathophysiology Research Template

2026-03-03
Falcon MONDO:0005825 Model: Edison Scientific Literature 34 citations

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

  • Disease Name: Leptospirosis
  • MONDO ID: (if available)
  • Category: Infectious

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Leptospirosis. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

  • What are the primary pathophysiological mechanisms?
  • What molecular pathways are dysregulated?
  • What cellular processes are affected?

2. Key Molecular Players

  • Genes/Proteins: Which genes are causally involved or implicated?
  • Chemical Entities: What metabolites, drugs, or small molecules are relevant?
  • Cell Types: Which cell types are primarily affected?
  • Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

  • What biological processes (GO terms) are disrupted?
  • Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

  • Where in the cell do key processes occur?
  • Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

  • What is the sequence of events from initial trigger to clinical manifestation?
  • Are there distinct stages or phases?

6. Phenotypic Manifestations

  • What are the key clinical phenotypes?
  • How do they relate to the underlying mechanisms?

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology of Leptospirosis (molecular and cellular mechanisms) — 2023–2024 evidence-focused report

Target disease - Disease: Leptospirosis (infectious zoonosis caused by pathogenic Leptospira spp.) (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5) - MONDO ID: Not retrieved from the current evidence set.

1) Key concepts and definitions (current understanding)

1.1 Disease concept and etiologic agent Leptospirosis is caused by pathogenic spirochetes of the genus Leptospira that are motile, diderm bacteria with an outer envelope containing lipopolysaccharide-like molecules and abundant surface proteins implicated in virulence (e.g., OmpL1, LipL32, LipL41, LipL21, Loa22, LigA). (goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4)

1.2 Core pathophysiologic framing A mechanistic framework emerging from recent reviews describes leptospirosis as a multi-organ, vascular/inflammatory disease driven by (i) early bacteremia and dissemination, (ii) immune recognition dominated by atypical pattern-recognition pathways (notably TLR2), (iii) host-damaging inflammation (cytokines, inflammasome), and (iv) organ-tropic injury, especially renal proximal tubule colonization with electrolyte transport dysfunction and tubulointerstitial inflammation/fibrosis. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, chou2023leptospirosiskidneydisease pages 1-2, chou2023leptospirosiskidneydisease pages 2-3, goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4)

1.3 Biphasic clinical-immunologic course A biphasic course is described, with an acute (often ~1 week) phase and an “immunological phase” beginning ~5–14 days after infection, consistent with transition from bacteremia to immune-mediated tissue injury and/or complications. (chou2023leptospirosiskidneydisease pages 1-2)

2) Core pathophysiology: molecular pathways and cellular processes

2.1 Entry, dissemination, and early systemic phase Leptospira can rapidly penetrate the host, produce bacteremia, and disseminate via circulation to spleen, liver, lungs, and kidneys; a cited peak blood load occurs around day 5. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5)

2.2 Innate sensing and inflammatory signaling (TLRs, NF-κB, chemokines)

Atypical LPS/LLS signaling bias toward TLR2 Leptospiral LPS-like substances (LLS) have atypical innate immune properties: compared with Enterobacteriaceae LPS, they “do not trigger macrophages via TLR4 but instead signal via TLR2,” and impaired TLR4–TRIF signaling is linked to decreased TRIF/RANTES-dependent nitric oxide and reduced CD40 on dendritic cells, potentially shaping adaptive responses. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4)

TLR2 as a central node (systematic review, 2024) A 2024 systematic review synthesized evidence that TLR2 responses during leptospirosis are associated with increased TLR2 expression and broad cytokine/effector programs, including IL6, IL8, IL-1β, TNFα, IFNγ, IL10, CCL2/MCP-1, COX2, and iNOS/ROS/RNS signatures. (kappagoda2024roleoftolllike pages 1-2)

Renal epithelial inflammatory signaling Kidney-focused evidence indicates that LipL32 (a major outer membrane protein) binds TLR2 on renal tubular epithelial cells and triggers inflammatory signaling (NF-κB/TNF axis) contributing to kidney injury and potentially chronic sequelae. (chou2023leptospirosiskidneydisease pages 1-2)

2.3 Inflammasome activation (NLRP3) and cytokine amplification A leptospiral glycolipoprotein (GLP; described as an endotoxin-like fraction) activates monocytes to secrete TNF-α, IL-10, and IL-6 and increases activation markers (e.g., CD69). GLP can synergize with LPS to induce IL-1β via the NLRP3 inflammasome, supporting an inflammasome-driven amplification loop in severe disease. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5) Mechanistically, this integration of bacterial ligands, TLRs, Na/K-ATPase signaling, NF-κB, and NLRP3 is explicitly summarized in the “Na/K-ATPase signalosome” schematic figure. (goncalvesdealbuquerque2023cellularpathophysiologyof media 2494c60d)

2.4 Complement dysregulation and immune evasion (factor H, MAC) A 2024 Infection and Immunity study provides direct mechanistic evidence that a leptospiral TolC outer membrane efflux protein supports complement evasion: recombinant TolC binds factor H (FH) and C3b; “rTolC-bound FH retained cofactor activity for C3b cleavage,” and rTolC inhibited membrane attack complex (MAC) deposition via both alternative and classical complement pathways. Blocking surface TolC reduced FH acquisition and increased MAC deposition on leptospires, consistent with protection from complement-mediated killing. (hota2024unveilingtheimpact pages 1-3)

2.5 Oxidative stress and ROS balance (pathogen defense vs host killing) Pathogenic Leptospira species are described as well equipped to sustain oxidative stress inside hosts; this capacity is considered important for virulence. (osoriorodriguez2024acutekidneyinjury pages 2-4) A 2023 multi-omics infection study identified oxidative stress defense factors (e.g., KatE catalase) as part of the leptospiral arsenal during macrophage interaction and highlighted upregulation of TolC-family proteins and a hemolysin linked to pulmonary hemorrhage. (kavela2023useofan pages 15-17)

3) Key molecular players (pathogen and host) with knowledge-base-style annotations

3.1 Pathogen virulence factors (Leptospira proteins/toxins) — selected, evidence-backed - LipL32: major abundant/immunogenic surface protein; binds TLR2 on renal tubular cells to trigger inflammatory signaling implicated in kidney injury. (chou2023leptospirosiskidneydisease pages 1-2, goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5) - LipL21: (i) shields peptidoglycan from NOD1/NOD2 sensing by preventing muropeptide generation; (ii) is required for acute disease in vivo in a CRISPRi hamster model (avirulent when knocked down). (fernandes2023evaluationofleptospira pages 12-14, goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5) - LipL41: CRISPRi knockdown produced only modest attenuation in one model; transposon mutant reportedly remained virulent (contextual evidence within CRISPRi study). (fernandes2023evaluationofleptospira pages 11-12) - OmpL1: CRISPRi silencing appears lethal/essential in Leptospira, implying a critical role in bacterial viability (and by extension, pathogenesis capacity). (fernandes2023evaluationofleptospira pages 12-14, fernandes2023evaluationofleptospira pages 1-2) - Loa22 (OmpA-like): upregulated during host interaction; described to bind ECM components and TLR2 to induce proinflammatory responses; Loa22 mutants are described as attenuated in animal models (as cited in multi-omics analysis). (kavela2023useofan pages 15-17) - LigA/LigB (leptospiral immunoglobulin-like adhesins): bind extracellular matrix proteins (collagen/laminin/fibronectin/fibrinogen); LigA/LigB were upregulated in LipL32 knockdown virulence remodeling and are considered central adhesins. (kavela2023useofan pages 15-17, goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, fernandes2023evaluationofleptospira pages 11-12) - TolC: binds factor H and C3b, supports C3b cleavage cofactor activity, and reduces MAC deposition (complement evasion). (hota2024unveilingtheimpact pages 1-3) - GLP (glycolipoprotein; endotoxin-like): cytotoxic membrane injury/vacuolation; inhibits Na/K-ATPase across organs; activates monocytes and synergizes to induce IL-1β via NLRP3 inflammasome. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, osoriorodriguez2024acutekidneyinjury pages 2-4) - Hemolysin SphH: forms pores in mammalian cells, linked to hemorrhage and barrier disruption. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5)

3.2 Host genes/proteins (HGNC symbols) and roles in leptospirosis pathophysiology - TLR2 (HGNC: TLR2): central pattern-recognition receptor; associated with broad cytokine/effector induction in leptospirosis models and human studies. (kappagoda2024roleoftolllike pages 1-2) - TLR4 (HGNC: TLR4): human TLR4 recognition of leptospiral LPS is limited/atypical; impaired TLR4–TRIF axis is noted in mechanistic summaries. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4) - NOD1, NOD2 (HGNC: NOD1, NOD2): cytosolic PRRs; LipL21-mediated peptidoglycan shielding blocks NOD1/NOD2 recognition. (fernandes2023evaluationofleptospira pages 12-14, goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5) - NLRP3 (HGNC: NLRP3): inflammasome component; GLP synergy supports IL-1β induction via NLRP3 in mechanistic summaries. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5) - IL1B, IL6, TNF, IL10 (HGNC: IL1B, IL6, TNF, IL10): cytokines repeatedly implicated in kidney inflammation and systemic injury signatures. (chou2023leptospirosiskidneydisease pages 1-2, chou2023leptospirosiskidneydisease pages 2-3, kappagoda2024roleoftolllike pages 1-2) - CCL2/MCP-1 (HGNC: CCL2): elevated in leptospirosis kidney disease and in TLR2-linked response signatures. (chou2023leptospirosiskidneydisease pages 2-3, kappagoda2024roleoftolllike pages 1-2) - HAVCR1/KIM-1 (HGNC: HAVCR1) and LCN2/NGAL (HGNC: LCN2): kidney injury biomarkers elevated in leptospirosis-associated kidney injury models and/or patients. (chou2023leptospirosiskidneydisease pages 2-3) - STAT3 (HGNC: STAT3) and TGFB1 (HGNC: TGFB1): implicated in maladaptive repair/fibrosis pathways in leptospirosis kidney disease; AKI-to-CKD transition includes TEC STAT3 activation and TGF-β1/SMAD-associated fibrosis. (osoriorodriguez2024acutekidneyinjury pages 2-4, chou2023leptospirosiskidneydisease pages 2-3) - CFH (HGNC: CFH), C3 (HGNC: C3): complement factors targeted by TolC binding (FH, C3b) to inhibit MAC deposition and promote immune evasion. (hota2024unveilingtheimpact pages 1-3)

3.3 Cell types (Cell Ontology-style labels; examples) and affected processes - Renal proximal tubule epithelial cell: primary niche/lesion site; TLR2-driven inflammation and transporter dysfunction contribute to non-oliguric, hypokalemic AKI patterns. (osoriorodriguez2024acutekidneyinjury pages 2-4, chou2023leptospirosiskidneydisease pages 1-2) - Monocyte/macrophage: phagocytosis with incomplete killing; key source of cytokines; targeted by recent host–microbiome therapeutic concepts increasing ROS-mediated killing. (osoriorodriguez2024acutekidneyinjury pages 2-4, chen2024gutmicrobiotaderivedbutyrate pages 1-2) - Dendritic cell: affected by impaired TLR4–TRIF signaling (e.g., altered CD40 expression) in leptospiral LLS models. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4) - Neutrophil: implicated via immune evasion mechanisms (LipL21-associated functions discussed in CRISPRi study context); pulmonary hemorrhage/ARDS clinical phenotypes often involve neutrophil-driven injury pathways in critical illness contexts. (fernandes2023evaluationofleptospira pages 12-14) - Endothelial cell: vascular barrier disruption and hemorrhage are central in severe disease (e.g., SphH pore formation). (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5)

3.4 Anatomical locations (UBERON-style labels; examples) - Kidney: proximal tubule, renal interstitium (tubulointerstitial nephritis; fibrosis progression). (osoriorodriguez2024acutekidneyinjury pages 2-4, chou2023leptospirosiskidneydisease pages 2-3) - Liver: hepatic dissemination; LipL21 knockdown reduced liver burdens while still allowing kidney colonization, implying organ-specific dissemination requirements. (fernandes2023evaluationofleptospira pages 12-14) - Lung: ARDS/pulmonary hemorrhage is a severe complication; pulmonary colonization/dissemination is part of early bacteremia and severe phenotypes. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, milovanovic2024extracorporeallifesupport pages 1-2)

3.5 Chemical entities (CHEBI-style identifiers; examples) - Butyrate (short-chain fatty acid): gut microbiota-derived metabolite that improves survival in hamster leptospirosis by enhancing macrophage ROS via HDAC3 inhibition and monocarboxylate transport (MCT). (chen2024gutmicrobiotaderivedbutyrate pages 1-2) - Reactive oxygen species (ROS): host antimicrobial effector enhanced by butyrate; also a stress that pathogenic Leptospira resist via antioxidant systems. (chen2024gutmicrobiotaderivedbutyrate pages 1-2, kavela2023useofan pages 15-17) - Electrolytes (K+, Na+): transporter dysfunction and Na/K-ATPase inhibition contribute to hypokalemia and sodium handling changes. (osoriorodriguez2024acutekidneyinjury pages 2-4)

4) Biological processes (GO-style) disrupted in leptospirosis (examples for annotation) - Innate immune response; Toll-like receptor signaling pathway (TLR2-biased recognition). (goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4, kappagoda2024roleoftolllike pages 1-2) - Cytokine-mediated signaling pathway (IL-6/TNF/IL-1β/IL-10 axes). (chou2023leptospirosiskidneydisease pages 2-3, kappagoda2024roleoftolllike pages 1-2) - Complement activation and regulation; inhibition of membrane attack complex assembly via pathogen factor-H acquisition. (hota2024unveilingtheimpact pages 1-3) - Inflammasome complex assembly / IL-1β production (NLRP3-linked). (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, goncalvesdealbuquerque2023cellularpathophysiologyof media 2494c60d) - Epithelial ion transport and homeostasis (Na/K-ATPase-associated transport dysfunction). (osoriorodriguez2024acutekidneyinjury pages 2-4, goncalvesdealbuquerque2023cellularpathophysiologyof media e2659fea) - Extracellular matrix organization, fibrotic process, and maladaptive repair (TGF-β1/SMAD; Wnt/β-catenin; STAT3-associated TEC injury programs). (chou2023leptospirosiskidneydisease pages 2-3) - Response to oxidative stress (host ROS killing vs leptospiral antioxidant defenses). (chen2024gutmicrobiotaderivedbutyrate pages 1-2, kavela2023useofan pages 15-17)

5) Cellular components (GO-CC-style) where key processes occur - Plasma membrane and outer membrane interface: TLR2 signaling initiated by surface lipoproteins (LipL32), and Na/K-ATPase inhibition/signaling at the plasma membrane. (chou2023leptospirosiskidneydisease pages 1-2, goncalvesdealbuquerque2023cellularpathophysiologyof media e2659fea) - Extracellular space/blood: bacteremia dissemination; complement interactions (FH/C3b/MAC). (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, hota2024unveilingtheimpact pages 1-3) - Inflammasome complex (cytosolic): NLRP3-mediated IL-1β induction in immune cells in response to GLP synergy. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, goncalvesdealbuquerque2023cellularpathophysiologyof media 2494c60d)

6) Disease progression (sequence of events)

Stage A: Exposure and penetration Exposure occurs via environmental/animal reservoirs (commonly rodents per reviews), with host penetration followed by rapid systemic spread. (petakh2024corticosteroidtreatmentfor pages 1-2, goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5)

Stage B: Septicemic dissemination and early organ seeding Early bacteremia disseminates leptospires to spleen, liver, lungs, and kidneys; blood burden peaks around day 5 in cited models. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5)

Stage C: Organ-specific injury programs Kidney: proximal tubule colonization and tubulointerstitial nephritis drive AKI, with mechanistic contributions from outer membrane proteins and GLP-mediated Na/K-ATPase inhibition and transporter dysfunction, causing electrolyte wasting, polyuria and hemodynamic stress. (osoriorodriguez2024acutekidneyinjury pages 2-4) Progression to CKD: persistent cytokine programs and profibrotic pathways (TGF-β1/SMAD, Wnt/β-catenin; STAT3, TEC arrest/senescence) support maladaptive repair and fibrosis in leptospirosis kidney disease. (chou2023leptospirosiskidneydisease pages 2-3)

Stage D: Severe complications and immune-mediated damage Severe phenotypes include pulmonary hemorrhage/ARDS and Weil’s disease, associated with high mortality; hemorrhage mechanisms include pore-forming hemolysins (SphH) and cytotoxic membrane injury (GLP). (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5, milovanovic2024extracorporeallifesupport pages 1-2)

7) Phenotypic manifestations (HP-style examples) and mechanistic linkage - Fever/headache/conjunctival suffusion: common in confirmed acute leptospirosis cohorts and consistent with systemic inflammatory response. (uriberestrepo2024clinicalpresentationof pages 1-2) - Acute kidney injury (AKI): frequent complication; linked to proximal tubule colonization, tubulointerstitial nephritis, and Na/K-ATPase / transporter dysfunction; may be non-oliguric and hypokalemic. (chou2023leptospirosiskidneydisease pages 1-2, osoriorodriguez2024acutekidneyinjury pages 2-4) - Jaundice/hepatic dysfunction (Weil’s disease): severe manifestation alongside renal dysfunction; linked to systemic dissemination and inflammatory injury. (petakh2024currenttreatmentoptions pages 1-2) - Pulmonary hemorrhage and ARDS: severe manifestation; in severe disease may have mortality up to ~50% according to ECLS review, and is linked to vascular barrier injury and hemorrhagic mechanisms (e.g., SphH). (milovanovic2024extracorporeallifesupport pages 1-2, goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5)

8) Recent developments and latest research (prioritizing 2023–2024)

8.1 2024: Complement evasion mechanism via TolC The discovery/characterization of TolC as a factor-H and C3b binding surface protein that inhibits MAC deposition provides a concrete, targetable complement-evasion mechanism supporting systemic persistence and tissue colonization. (hota2024unveilingtheimpact pages 1-3)

8.2 2024: Host–microbiome metabolite axis (butyrate → HDAC3 → ROS) A 2024 mBio study demonstrates that microbiota-derived butyrate improves hamster survival in acute leptospirosis by enhancing macrophage ROS bactericidal activity via an MCT-dependent HDAC3 inhibition mechanism (“butyrate-MCT-HDAC3i-ROS signaling axis”). (chen2024gutmicrobiotaderivedbutyrate pages 1-2)

8.3 2023: Functional genetics (CRISPRi) for virulence factor essentiality CRISPRi knockdown in Leptospira shows that OmpL1 is essential (lethal phenotype when silenced) and LipL21 is essential for acute disease in vivo (avirulent when knocked down), while LipL32 knockdown can paradoxically augment virulence with compensatory upregulation of other virulence factors (e.g., LigA/LigB). (fernandes2023evaluationofleptospira pages 12-14, fernandes2023evaluationofleptospira pages 11-12, fernandes2023evaluationofleptospira pages 1-2)

9) Current applications and real-world implementations (diagnostics, therapy, prevention)

9.1 Diagnostics Recent clinical reviews reiterate that the microscopic agglutination test (MAT) remains the gold-standard and most commonly used diagnostic method, while PCR is more sensitive but less available in low-resource settings. (petakh2024corticosteroidtreatmentfor pages 1-2) A 2024 Colombia prospective study operationalized PCR confirmation in suspected febrile patients and found 37% PCR-confirmation among 100 suspected cases, illustrating real-world diagnostic triage in endemic febrile syndrome settings. (uriberestrepo2024clinicalpresentationof pages 1-2)

9.2 Treatment and supportive care Antibiotic therapy remains first-line; a 2024 treatment mini-review describes real-world variability in antibiotic use and reported commonly used agents (e.g., ceftriaxone, doxycycline, ampicillin, penicillin) and notes doxycycline may reduce duration of infection by ~2 days. (petakh2024currenttreatmentoptions pages 1-2) Adjunctive immunomodulation: a 2024 meta-analysis found corticosteroid evidence remains inconclusive (observational studies suggest possible benefit for pulmonary complications; the single randomized trial showed no significant benefit), highlighting ongoing uncertainty and the need for better trials. (petakh2024corticosteroidtreatmentfor pages 1-2) Rescue therapy for severe ARDS: extracorporeal life support (ECLS/ECMO) is used as salvage therapy; a 2024 narrative review identified 43 reported ECLS-treated cases with overall mortality of 16%, but evidence is limited and subject to bias; pulmonary hemorrhage/ARDS mortality in severe disease can be up to 50%. (milovanovic2024extracorporeallifesupport pages 1-2)

9.3 Vaccines and prevention A 2023 recombinant vaccine review notes that commercial vaccines are mainly inactivated whole-cell formulations used in veterinary contexts, while recombinant vaccine development (e.g., LipL32 and Lig proteins) faces persistent challenges (platform/delivery, adjuvants, correlates of protection, achieving renal clearance/sterile immunity). (oliveira2023challengesandstrategies pages 1-2)

10) Relevant recent statistics and data (2023–2024)

10.1 Global burden Multiple 2024 sources converge on an annual global burden around ~1.03 million cases and ~58,900–60,000 deaths. (petakh2024corticosteroidtreatmentfor pages 1-2, petakh2024currenttreatmentoptions pages 1-2, uriberestrepo2024clinicalpresentationof pages 1-2)

10.2 Clinical phenotype frequencies (2024 cohort) In PCR-confirmed cases in Urabá, Colombia (n=37): headache 91.9%, chills/sweating 80.6%, nausea 75%, dizziness 74.3%, vomiting 61.1%, congestion 56.8%, conjunctival suffusion 51.4%; jaundice 8.3%, anuria/oliguria 21.6%; complications 21.6% with pulmonary complications 75% of those; case fatality 2.7% (1 death). (uriberestrepo2024clinicalpresentationof pages 1-2)

10.3 ECLS/ECMO outcomes (2024 narrative review) ECLS-treated leptospirosis cases (n=43 across reports): overall mortality 16%; acute renal failure requiring renal replacement therapy is a frequent major complication (reported 74% in review context). (milovanovic2024extracorporeallifesupport pages 1-2, milovanovic2024extracorporeallifesupport pages 7-9)

11) Evidence items (PMID-anchored where present in the retrieved evidence) - Leptospiral LPS activates via TLR2: “Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism” (Nature Immunology; PMID: 11276206; DOI: 10.1038/86354). (xie2024neutralizinggutderivedlipopolysaccharide pages 23-23) - Na/K-ATPase/GLP → NLRP3 inflammasome (cited within TLR2 systematic review excerpt): “Downregulation of the Na/K-ATPase pump by leptospiral glycolipoprotein activates the NLRP3 inflammasome.” (J Immunol. 2012; PMID: 22323544; DOI: 10.4049/jimmunol.1101987). (kappagoda2024roleoftolllike pages 21-22)

12) Mechanistic visual evidence The GLP→Na/K-ATPase inhibition model and the integrated Na/K-ATPase signalosome schematic (linking TLRs, NF-κB, and NLRP3) are captured in figures from a 2023 mechanistic review and support the proposed ion-transport/inflammation coupling in leptospirosis pathophysiology. (goncalvesdealbuquerque2023cellularpathophysiologyof media e2659fea, goncalvesdealbuquerque2023cellularpathophysiologyof media 2494c60d)

Limitations of this report (based on available evidence set) - Some organ-specific mechanisms (e.g., detailed endothelial glycocalyx injury pathways; NET-mediated lung microthrombosis; quantitative complement gene associations; comprehensive metabolomics) were not directly extractable from the currently retrieved full-text excerpts and would require targeted retrieval of additional primary pulmonary-vascular studies.

References

  1. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 4-5): Cassiano Felippe Gonçalves-de-Albuquerque, Carolina Medina Coeli da Cunha, Léo Victor Grimaldi de Castro, Caroline de Azevedo Martins, Marcos Roberto Colombo Barnese, Patrícia Burth, and Mauricio Younes-Ibrahim. Cellular pathophysiology of leptospirosis: role of na/k-atpase. Microorganisms, 11:1695, Jun 2023. URL: https://doi.org/10.3390/microorganisms11071695, doi:10.3390/microorganisms11071695. This article has 20 citations.

  2. (goncalvesdealbuquerque2023cellularpathophysiologyof pages 2-4): Cassiano Felippe Gonçalves-de-Albuquerque, Carolina Medina Coeli da Cunha, Léo Victor Grimaldi de Castro, Caroline de Azevedo Martins, Marcos Roberto Colombo Barnese, Patrícia Burth, and Mauricio Younes-Ibrahim. Cellular pathophysiology of leptospirosis: role of na/k-atpase. Microorganisms, 11:1695, Jun 2023. URL: https://doi.org/10.3390/microorganisms11071695, doi:10.3390/microorganisms11071695. This article has 20 citations.

  3. (chou2023leptospirosiskidneydisease pages 1-2): Li-Fang Chou, Huang-Yu Yang, Cheng-Chieh Hung, Ya-Chung Tian, Shen-Hsing Hsu, and Chih-Wei Yang. Leptospirosis kidney disease: evolution from acute to chronic kidney disease. Biomedical Journal, 46:100595, Aug 2023. URL: https://doi.org/10.1016/j.bj.2023.100595, doi:10.1016/j.bj.2023.100595. This article has 32 citations.

  4. (chou2023leptospirosiskidneydisease pages 2-3): Li-Fang Chou, Huang-Yu Yang, Cheng-Chieh Hung, Ya-Chung Tian, Shen-Hsing Hsu, and Chih-Wei Yang. Leptospirosis kidney disease: evolution from acute to chronic kidney disease. Biomedical Journal, 46:100595, Aug 2023. URL: https://doi.org/10.1016/j.bj.2023.100595, doi:10.1016/j.bj.2023.100595. This article has 32 citations.

  5. (kappagoda2024roleoftolllike pages 1-2): Chamila Kappagoda, Indika Senavirathna, Thilini Agampodi, and Suneth Buddhika Agampodi. Role of toll-like receptor 2 during infection of leptospira spp: a systematic review. PLOS ONE, 19:e0312466, Dec 2024. URL: https://doi.org/10.1371/journal.pone.0312466, doi:10.1371/journal.pone.0312466. This article has 1 citations and is from a peer-reviewed journal.

  6. (goncalvesdealbuquerque2023cellularpathophysiologyof media 2494c60d): Cassiano Felippe Gonçalves-de-Albuquerque, Carolina Medina Coeli da Cunha, Léo Victor Grimaldi de Castro, Caroline de Azevedo Martins, Marcos Roberto Colombo Barnese, Patrícia Burth, and Mauricio Younes-Ibrahim. Cellular pathophysiology of leptospirosis: role of na/k-atpase. Microorganisms, 11:1695, Jun 2023. URL: https://doi.org/10.3390/microorganisms11071695, doi:10.3390/microorganisms11071695. This article has 20 citations.

  7. (hota2024unveilingtheimpact pages 1-3): Saswat Hota and Manish Kumar. Unveiling the impact of leptospira tolc efflux protein on host tissue adherence, complement evasion, and diagnostic potential. Infection and Immunity, Nov 2024. URL: https://doi.org/10.1128/iai.00419-24, doi:10.1128/iai.00419-24. This article has 3 citations and is from a peer-reviewed journal.

  8. (osoriorodriguez2024acutekidneyinjury pages 2-4): Elber Osorio-Rodríguez, Dairo Rodelo-Barrios, Carlos Rebolledo-Maldonado, Alberto Polo-Barranco, Jhonny Patiño-Patiño, Mauricio Aldana-Roa, Valeria Sánchez-Daza, Emily Sierra-Ordoñez, and Alfonso Bettin-Martínez. Acute kidney injury associated with severe leptospirosis: fatal re-emerging disease in latin america. Kidney and Dialysis, 4:78-92, Apr 2024. URL: https://doi.org/10.3390/kidneydial4020006, doi:10.3390/kidneydial4020006. This article has 8 citations.

  9. (kavela2023useofan pages 15-17): Sridhar Kavela, Pallavi Vyas, Jusail CP, Sandeep K. Kushwaha, Subeer S. Majumdar, and Syed M. Faisal. Use of an integrated multi-omics approach to identify molecular mechanisms and critical factors involved in the pathogenesis of leptospira. Apr 2023. URL: https://doi.org/10.1128/spectrum.03135-22, doi:10.1128/spectrum.03135-22. This article has 12 citations and is from a domain leading peer-reviewed journal.

  10. (fernandes2023evaluationofleptospira pages 12-14): Luis G. V. Fernandes, Aline F. Teixeira, and Ana L. T. O. Nascimento. Evaluation of leptospira interrogans knockdown mutants for lipl32, lipl41, lipl21, and ompl1 proteins. Frontiers in Microbiology, Jun 2023. URL: https://doi.org/10.3389/fmicb.2023.1199660, doi:10.3389/fmicb.2023.1199660. This article has 14 citations and is from a peer-reviewed journal.

  11. (fernandes2023evaluationofleptospira pages 11-12): Luis G. V. Fernandes, Aline F. Teixeira, and Ana L. T. O. Nascimento. Evaluation of leptospira interrogans knockdown mutants for lipl32, lipl41, lipl21, and ompl1 proteins. Frontiers in Microbiology, Jun 2023. URL: https://doi.org/10.3389/fmicb.2023.1199660, doi:10.3389/fmicb.2023.1199660. This article has 14 citations and is from a peer-reviewed journal.

  12. (fernandes2023evaluationofleptospira pages 1-2): Luis G. V. Fernandes, Aline F. Teixeira, and Ana L. T. O. Nascimento. Evaluation of leptospira interrogans knockdown mutants for lipl32, lipl41, lipl21, and ompl1 proteins. Frontiers in Microbiology, Jun 2023. URL: https://doi.org/10.3389/fmicb.2023.1199660, doi:10.3389/fmicb.2023.1199660. This article has 14 citations and is from a peer-reviewed journal.

  13. (chen2024gutmicrobiotaderivedbutyrate pages 1-2): Xi Chen, Xufeng Xie, Ni Sun, Xin Liu, Jiuxi Liu, Wenlong Zhang, and Yongguo Cao. Gut microbiota-derived butyrate improved acute leptospirosis in hamster via promoting macrophage ros mediated by hdac3 inhibition. Oct 2024. URL: https://doi.org/10.1128/mbio.01906-24, doi:10.1128/mbio.01906-24. This article has 7 citations and is from a domain leading peer-reviewed journal.

  14. (milovanovic2024extracorporeallifesupport pages 1-2): Lazar Milovanovic, Gurmeet Singh, Derek Townsend, Jayan Nagendran, and Wendy Sligl. Extracorporeal life support for severe leptospirosis: case series and narrative review. Journal of the Association of Medical Microbiology and Infectious Disease Canada, Sep 2024. URL: https://doi.org/10.3138/jammi-2023-0033, doi:10.3138/jammi-2023-0033. This article has 5 citations.

  15. (goncalvesdealbuquerque2023cellularpathophysiologyof media e2659fea): Cassiano Felippe Gonçalves-de-Albuquerque, Carolina Medina Coeli da Cunha, Léo Victor Grimaldi de Castro, Caroline de Azevedo Martins, Marcos Roberto Colombo Barnese, Patrícia Burth, and Mauricio Younes-Ibrahim. Cellular pathophysiology of leptospirosis: role of na/k-atpase. Microorganisms, 11:1695, Jun 2023. URL: https://doi.org/10.3390/microorganisms11071695, doi:10.3390/microorganisms11071695. This article has 20 citations.

  16. (petakh2024corticosteroidtreatmentfor pages 1-2): Pavlo Petakh, Valentyn Oksenych, and Oleksandr Kamyshnyi. Corticosteroid treatment for leptospirosis: a systematic review and meta-analysis. Journal of Clinical Medicine, 13:4310, Jul 2024. URL: https://doi.org/10.3390/jcm13154310, doi:10.3390/jcm13154310. This article has 11 citations.

  17. (uriberestrepo2024clinicalpresentationof pages 1-2): Pablo Uribe-Restrepo, Janeth Perez-Garcia, Margarita Arboleda, Claudia Munoz-Zanzi, and Piedad Agudelo-Florez. Clinical presentation of human leptospirosis in febrile patients: urabá, colombia. Sep 2024. URL: https://doi.org/10.1371/journal.pntd.0012449, doi:10.1371/journal.pntd.0012449. This article has 12 citations and is from a domain leading peer-reviewed journal.

  18. (petakh2024currenttreatmentoptions pages 1-2): Pavlo Petakh, Payam Behzadi, Valentyn Oksenych, and Oleksandr Kamyshnyi. Current treatment options for leptospirosis: a mini-review. Frontiers in Microbiology, Apr 2024. URL: https://doi.org/10.3389/fmicb.2024.1403765, doi:10.3389/fmicb.2024.1403765. This article has 51 citations and is from a peer-reviewed journal.

  19. (oliveira2023challengesandstrategies pages 1-2): Natasha Rodrigues de Oliveira, Francisco Denis Souza Santos, Vitória Adrielly Catschor dos Santos, Mara Andrade Colares Maia, Thaís Larré Oliveira, and Odir Antônio Dellagostin. Challenges and strategies for developing recombinant vaccines against leptospirosis: role of expression platforms and adjuvants in achieving protective efficacy. Pathogens, 12:787, May 2023. URL: https://doi.org/10.3390/pathogens12060787, doi:10.3390/pathogens12060787. This article has 15 citations.

  20. (milovanovic2024extracorporeallifesupport pages 7-9): Lazar Milovanovic, Gurmeet Singh, Derek Townsend, Jayan Nagendran, and Wendy Sligl. Extracorporeal life support for severe leptospirosis: case series and narrative review. Journal of the Association of Medical Microbiology and Infectious Disease Canada, Sep 2024. URL: https://doi.org/10.3138/jammi-2023-0033, doi:10.3138/jammi-2023-0033. This article has 5 citations.

  21. (xie2024neutralizinggutderivedlipopolysaccharide pages 23-23): Xufeng Xie, Xi Chen, Shilei Zhang, Jiuxi Liu, Wenlong Zhang, and Yongguo Cao. Neutralizing gut-derived lipopolysaccharide as a novel therapeutic strategy for severe leptospirosis. May 2024. URL: https://doi.org/10.7554/elife.96065.2, doi:10.7554/elife.96065.2. This article has 11 citations.

  22. (kappagoda2024roleoftolllike pages 21-22): Chamila Kappagoda, Indika Senavirathna, Thilini Agampodi, and Suneth Buddhika Agampodi. Role of toll-like receptor 2 during infection of leptospira spp: a systematic review. PLOS ONE, 19:e0312466, Dec 2024. URL: https://doi.org/10.1371/journal.pone.0312466, doi:10.1371/journal.pone.0312466. This article has 1 citations and is from a peer-reviewed journal.